The future of lipid guidelines.

Area of Science:

• Cardiovascular Medicine
• Clinical Guidelines
• Evidence-Based Practice

Background:

• Guideline development is influenced by new data and methodologies.
• Treatment recommendations can undergo paradigm shifts based on evolving evidence.

Purpose of the Study:

• To analyze the 2013 American College of Cardiology/American Heart Association cholesterol guideline as an example of a paradigm shift in cardiovascular prevention.
• To highlight the move from a "treat to cholesterol goal" approach to evidence-based statin recommendations.

Main Methods:

• Review of the 2013 ACC/AHA cholesterol guideline.
• Analysis of findings from randomized clinical trials informing the guideline.
• Examination of new methodology in risk prediction and shared decision-making.

Main Results:

• The 2013 guideline shifted focus from cholesterol goals to statin use based on net benefit for atherosclerotic cardiovascular disease risk reduction.
• Statins were recommended for four patient groups with strong evidence of net benefit.
• Improved risk prediction equations and shared decision-making were emphasized for primary prevention in patients with LDL cholesterol ≤190 mg/dL.

Conclusions:

• Guidelines evolve with accumulating data, necessitating new treatment paradigms.
• Future guidelines will likely include non-statin therapies for cardiovascular prevention.
• Enhanced risk prediction, net benefit estimation, and shared decision-making are crucial for future guideline development.